11:31 AM EST - Immunovaccine Inc. : Announced an expansion of its ongoing collaboration with UConn Health. The collaboration is part of Immunovaccine’s DPX-NEO program, which is evaluating the anti-cancer activity of proprietary patient-specific epitopes developed at UConn Health and formulated in the Company’s DepoVax™-based vaccine formulation. Immunovaccine Inc.
shares T.IMV are trading up $0.16 at $2.07.
